You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Proton pump inhibitors and risk of gastric cancer in a case–control study
  1. Shih-Wei Lai1,2,
  2. Hsueh-Chou Lai3,4,
  3. Cheng-Li Lin1,5,
  4. Kuan-Fu Liao6,7
  1. 1 College of Medicine, China Medical University, Taichung, Taiwan
  2. 2 Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan
  3. 3 College of Chinese Medicine, China Medical University, Taichung, Taiwan
  4. 4 Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
  5. 5 Management Office for Health Data, China Medical University, Taichung, Taiwan
  6. 6 College of Medicine, Tzu Chi University, Hualien, Taiwan
  7. 7 Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung, Taiwan
  1. Correspondence to Dr Kuan-Fu Liao, Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung City, 427, Taiwan; kuanfuliaog{at}gmail.com

http://dx.doi.org/10.1136/gutjnl-2018-316371

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read four manuscripts published in Gut about the relationship between proton pump inhibitors use and gastric cancer.1–4 Proton pump inhibitors are widely used for the management of peptic ulcer disease, gastroesophageal reflux disease and eradication of Helicobacter pylori infection.5 However, its safety for long-term use has raised pubic concern.6 In order to clarify the relationship between proton pump inhibitors use and gastric cancer, we used the 2000–2013 database of Taiwan National Health Insurance Program to conduct a population-based case–control study. The study design and data source were adapted from previous studies.7 8 Subjects aged 20–84 years with newly diagnosed gastric cancer were selected as the cases. Subjects without gastric cancer were randomly selected from the same database as the matched controls. The index date was defined as the date of each case being diagnosed with gastric cancer. Both cases with gastric cancer and matched controls were matched with sex, age (every five years) and the year of index date. In order to reduce the latency bias, subjects whose first-time prescriptions for proton pump …

    View Full Text

    Footnotes

    • S-WL and H-CL contributed equally.

    • Contributors S-WL and H-CL contributed to the conception of the article, initiated the draft of the article, revised the article and contributed equally to the article. C-LL conducted the data analysis and revised the article. K-FL participated in the data interpretation and revised the article.

    • Funding This study was supported in part by the Ministry of Health and Welfare, Taiwan (MOHW107-TDU-B-212-123004).

    • Disclaimer This funding agency did not influence the study design, data collection and analysis, decision to publish or preparation of the manuscript.

    • Competing interests None declared.

    • Patient consent Not required.

    • Ethics approval The study was conducted in accordance with the Declaration of Helsinki. The study was approved by the Research Ethics Committee of China Medical University and Hospital in Taiwan (CMUH-104-REC2-115).

    • Provenance and peer review Not commissioned; externally peer reviewed.